Clinical trial
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive…
NCT00470704 · Nancy Lin, MD, Other · Completed
Key facts
| NCT number | NCT00470704 |
|---|---|
| Title | Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer |
| Official title | A Phase 2 Study of Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer |
| Lead sponsor | Nancy Lin, MD, Other |
| Collaborators | GlaxoSmithKline Industry Novartis |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Lapatinib, Herceptin |
| Enrollment | 87 |
| Start date | May 14, 2007 |
| Primary completion | Nov 30, 2013 |
| Completion | Aug 20, 2024 |
| First posted | May 8, 2007 |
| Last update posted | Dec 19, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: